List of Excipients in Branded Drug DG HEALTH ESOMEPRAZOLE MAGNESIUM

Generic Drugs Containing DG HEALTH ESOMEPRAZOLE MAGNESIUM

Company	Ingredient	NDC	Excipient
Dolgencorp LLC	esomeprazole	55910-250	FD&C BLUE NO. 1
Dolgencorp LLC	esomeprazole	55910-250	FD&C BLUE NO. 1 ALUMINUM LAKE
Dolgencorp LLC	esomeprazole	55910-250	FD&C RED NO. 3
Dolgencorp LLC	esomeprazole	55910-250	FERRIC OXIDE RED
Dolgencorp LLC	esomeprazole	55910-250	GELATIN
Dolgencorp LLC	esomeprazole	55910-250	GLYCERYL MONOSTEARATE

What are the Most Frequently-Used Excipients in DG HEALTH ESOMEPRAZOLE MAGNESIUM?

# Of NDCs	Excipient
1	ACACIA
1	D&C YELLOW NO. 10
3	FD&C BLUE NO. 1
1	FD&C BLUE NO. 1 ALUMINUM LAKE
3	FD&C RED NO. 3
2	FERRIC OXIDE RED

DG Health Esomeprazole Magnesium: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 1, 2026

DG Health Esomeprazole Magnesium is an over-the-counter delayed-release proton-pump inhibitor product positioned as a private-label alternative to Nexium 24HR. Its commercial value is driven by low-cost enteric delivery, reliable shelf life, retail distribution, and manufacturing scale rather than by a remaining branded patent moat. The principal excipient opportunity is optimization of the delayed-release multiparticulate system, including enteric coating, moisture protection, capsule presentation, and cost-efficient fill weights.

What is DG Health Esomeprazole Magnesium?

DG Health Esomeprazole Magnesium is an OTC product containing esomeprazole magnesium, generally supplied as a 20 mg delayed-release capsule for the treatment of frequent heartburn.

Product characteristic	Commercial description
Active ingredient	Esomeprazole magnesium
Common strength	20 mg
Dosage form	Delayed-release capsule
Therapeutic class	Proton-pump inhibitor
Primary indication	Frequent heartburn occurring two or more days per week
Regulatory positioning	OTC drug product
Reference commercial product	Nexium 24HR
Primary buyer	Dollar General retail customer
Competitive set	Store-brand esomeprazole, omeprazole, lansoprazole, and branded Nexium
Principal formulation requirement	Protection of esomeprazole from gastric acid until intestinal release

The active ingredient is acid-labile. A conventional immediate-release capsule would expose esomeprazole to gastric degradation and would not provide the intended pharmacological profile. The product therefore depends on delayed-release pellets or granules protected by an enteric polymer system.

The FDA-approved OTC labeling for esomeprazole 20 mg requires once-daily administration for a limited treatment course, generally up to 14 days, with repeat courses subject to label instructions.[1]

What excipients are important in DG Health Esomeprazole Magnesium?

The commercial formulation normally contains several excipient layers rather than a single inactive matrix. Exact excipient identity and concentration can vary by manufacturer, supply arrangement, and approved ANDA or NDA formulation.

Core pellet excipients

The pellet core may contain:

• Microcrystalline cellulose as a spheronization aid and structural diluent
• Sucrose or sugar spheres as a neutral starter core
• Povidone or another binder
• Crospovidone or related disintegrant, where needed
• Magnesium oxide or alkaline stabilizer
• Esomeprazole magnesium as the active pharmaceutical ingredient

The core must maintain mechanical integrity during coating, filling, transport, and storage. Excessive friability creates powder, weight variation, and dose-uniformity risks. Excessive hardness can delay drug release after the enteric coat dissolves.

Drug-layer excipients

Drug-layer systems commonly use a polymeric binder to attach esomeprazole magnesium to the pellet core. The drug layer must be sufficiently uniform to control dose distribution across pellets.

A basic development target is:

1. Uniform active deposition.
2. Low pellet agglomeration.
3. Minimal degradation during aqueous processing.
4. Consistent drug loading across production lots.

The manufacturing process must control suspension pH, solids content, spray rate, inlet temperature, and atomization. Esomeprazole is sensitive to acidic conditions, so the formulation generally favors an alkaline microenvironment.

Seal-coat excipients

A seal coat separates the drug layer from the enteric polymer. It can reduce chemical interaction between the active layer and the acidic or otherwise incompatible enteric coating.

Common seal-coat functions include:

• Preventing migration of the active ingredient
• Reducing moisture transfer
• Improving coating adhesion
• Limiting interaction with plasticizers
• Improving pellet surface uniformity

Hydroxypropyl methylcellulose, hydroxypropyl cellulose, or related film-forming polymers can be used in this layer, depending on the formulation architecture.

Enteric-coat excipients

The enteric coat is the most commercially important excipient subsystem. It prevents release in the stomach and dissolves at a higher intestinal pH.

Potential enteric polymers include:

• Methacrylic acid copolymers
• Cellulose acetate phthalate
• Polyvinyl acetate phthalate
• Hydroxypropyl methylcellulose phthalate

Commercial performance depends on polymer grade, coating weight, plasticizer selection, and curing conditions. Triethyl citrate, polyethylene glycol, or similar agents may be used as plasticizers. Talc or another anti-tacking agent can support coating efficiency.

The target is a dissolution profile that resists release in acidic media and releases rapidly after exposure to intestinal pH. A coating that is too thin can fail acid resistance. A coating that is too thick can delay release, increase capsule fill weight, and raise manufacturing cost.

Capsule-shell excipients

The capsule shell may use gelatin or a vegetarian polymer such as hypromellose. Colorants and opacifiers can support product identification, light protection, and retail differentiation.

A capsule-shell change may create an opportunity for:

• Vegetarian positioning
• Improved moisture control
• Reduced colorant burden
• Cleaner-label marketing
• Improved compatibility with automated filling equipment

These changes must remain compatible with the approved regulatory pathway and product performance specifications.

How does the excipient strategy affect product performance?

Excipient selection affects five commercial performance metrics: acid resistance, release timing, stability, dose uniformity, and manufacturing cost.

Excipient or subsystem	Primary function	Main failure mode
Neutral starter core	Pellet formation	Friability or poor drug loading
Binder	Active adhesion	Agglomeration or uneven coating
Alkalizing agent	Active stabilization	Excessive alkalinity or incompatibility
Seal coat	Layer separation	Moisture transfer or interlayer interaction
Enteric polymer	Gastric protection	Premature release or delayed intestinal release
Plasticizer	Film flexibility	Tackiness or accelerated aging
Anti-tacking agent	Coating efficiency	Rough film or impaired dissolution
Capsule shell	Presentation and protection	Moisture ingress or shell brittleness

For a private-label OTC product, the best formulation is rarely the one with the highest number of excipients. The more relevant objective is a robust formulation with a narrow process window, low coating weight, stable release performance, and reliable supply of critical polymers.

What formulation patents protect esomeprazole products?

Esomeprazole was developed as the S-enantiomer of omeprazole. Earlier patent protection covered the active compound and related pharmaceutical uses. Those rights have expired or no longer provide a meaningful barrier to routine generic and private-label entry in the United States.

Residual commercial protection is more likely to involve:

• Delayed-release pellet architecture
• Specific enteric-coating compositions
• Stabilization systems
• Multilayer dosage forms
• Specific dissolution profiles
• Combination products
• Pediatric or alternative dosage forms
• Manufacturing processes

The strongest surviving formulation claims would need to cover a commercially necessary feature that is difficult to design around. Broad claims to esomeprazole capsules are less likely to block current OTC products because multiple formulation routes are available.

The FDA Orange Book is relevant primarily to approved prescription and certain NDA products. DG Health is a private-label OTC product and ordinarily would not have an independent Orange Book patent estate comparable to a branded NDA product. Patent analysis must therefore distinguish the DG Health product from Nexium and from the ANDA or OTC authorization held by its contract manufacturer.[2]

When does esomeprazole lose exclusivity?

The practical market exclusivity for esomeprazole has already ended in the United States. Generic prescription esomeprazole products entered after expiry or resolution of key Nexium patent rights, and OTC store brands followed the commercial model established by Nexium 24HR.

Exclusivity category	Status for DG Health esomeprazole
New chemical entity exclusivity	Expired
Core compound patent protection	Expired
Prescription generic entry	Established
OTC market exclusivity	No meaningful product-specific moat
Current competitive barrier	Manufacturing, regulatory compliance, distribution, and retail economics
Biosimilar exclusivity	Not applicable

The product is a small-molecule drug, not a biologic. Biosimilar litigation and biologic reference-product exclusivity do not apply.

What is the Orange Book status of DG Health Esomeprazole Magnesium?

DG Health esomeprazole should not be analyzed as though its retail label itself were a standalone Orange Book-listed brand product. The relevant regulatory rights may sit with the manufacturer’s approved application, an OTC NDA, or an ANDA-related product authorization.

The Orange Book can identify:

• Reference listed drugs
• Approved applications
• Patent listings associated with eligible applications
• Pediatric exclusivity
• Certain regulatory exclusivity periods

It does not provide a complete record of every patent that may affect a private-label product. Manufacturing-process patents, trade secrets, supplier agreements, and non-Orange-Book formulation rights can remain commercially relevant.

For an acquisition or licensing review, the critical documents are the product’s NDC listing, FDA approval pathway, labeling, inactive-ingredient profile, manufacturing site, and any patent certifications associated with the underlying application.

Are Paragraph IV challenges relevant to DG Health esomeprazole?

Paragraph IV litigation was more relevant during the initial generic entry period for prescription esomeprazole. A generic applicant can use Paragraph IV certification to assert that a listed patent is invalid, unenforceable, or not infringed. A patent-holder lawsuit can trigger a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory conditions.[3]

For a mature OTC private-label product, Paragraph IV risk is usually less important than:

• Whether the product relies on an approved NDA or ANDA
• Whether listed patents remain enforceable
• Whether the formulation copies a protected release profile
• Whether the manufacturer has settled or licensed any remaining claims
• Whether the product can be reformulated without losing equivalence

A new entrant with a materially different pellet system may reduce litigation exposure by avoiding specific coating compositions or process limitations.

Which companies are challenging the esomeprazole market?

The competitive landscape includes branded, generic, and private-label suppliers.

Brand competitors

Nexium and Nexium 24HR established the commercial category and continue to provide consumer recognition. Brand pricing remains substantially above store-brand alternatives, but brand recognition can support premium placement.

Generic manufacturers

Generic manufacturers compete through pharmacy distribution, wholesale contracts, and retail channels. Their principal advantages are established regulatory files, validated manufacturing processes, and scale purchasing for active ingredient and enteric polymers.

Private-label suppliers

Private-label products are often manufactured by contract suppliers for retailers such as Dollar General, Walmart, CVS, Walgreens, and grocery chains. The retail brand controls shelf placement and consumer pricing, while the contract manufacturer controls much of the formulation, regulatory, and supply-chain infrastructure.

The most important competitive variable is often not the excipient list. It is delivered cost per sellable capsule, including active ingredient, coating materials, packaging, testing, freight, retailer margin, and inventory carrying cost.

What commercial opportunities exist in excipients?

The largest opportunity is a lower-cost, higher-throughput delayed-release platform that can support several proton-pump inhibitor products.

1. Enteric-polymer substitution

A supplier that offers a lower-cost methacrylic acid copolymer with equivalent dissolution performance could compete on coating cost. The opportunity requires:

• Comparable acid resistance
• Rapid intestinal release
• Stable film formation
• Low tackiness
• Consistent particle-size distribution
• Regulatory support for the new excipient grade

The supplier must demonstrate that the new material does not alter critical quality attributes.

2. Lower coating weight

A more efficient polymer and plasticizer combination could reduce coating weight. Lower coating weight can improve:

• Batch throughput
• Capsule capacity
• Material cost
• Drying time
• Energy consumption

The risk is reduced acid resistance or greater lot-to-lot variability. A small reduction in coating weight has commercial value only if dissolution and stability remain within specification.

3. Moisture-control systems

Moisture is a major stability concern for coated pellets and gelatin capsules. Opportunities include:

• Improved capsule-shell moisture barriers
• Desiccant-based packaging
• High-barrier blister films
• Foil-foil blister systems
• Moisture-resistant bottle closures
• Lower-water-activity excipient systems

A packaging upgrade can be more economical than a reformulation when degradation is driven primarily by environmental exposure.

4. Vegetarian capsule shells

Hypromellose capsules can support retailer requirements and consumer demand for non-gelatin products. The commercial advantage depends on cost, filling performance, shell moisture behavior, and compatibility with the existing capsule-filling line.

5. Ready-to-use coating dispersions

Pre-formulated coating systems can reduce development time and process variability. They may include polymer, plasticizer, anti-tacking agent, and pigment. The buyer pays more per kilogram but may reduce:

• Scale-up risk
• Operator burden
• Raw-material qualification work
• Batch-to-batch variability
• Development cycle time

6. Pediatric and alternative dosage forms

Potential extensions include:

• Sprinkle capsules
• Sachets containing delayed-release granules
• Orally disintegrating systems
• Lower-dose products
• Combination heartburn products

These products create new formulation and regulatory requirements. They also offer greater differentiation than another 20 mg delayed-release capsule.

How strong is the patent estate for DG Health esomeprazole?

The patent estate is commercially weak at the active-ingredient level and potentially moderate at the formulation level.

Patent layer	Relative strength	Commercial implication
Esomeprazole compound	Low	Core protection is expired
Standard 20 mg delayed-release capsule	Low to moderate	Multiple design-around routes
Specific pellet and coating systems	Moderate	May affect selected suppliers or formulations
Manufacturing process	Moderate	Can create confidential know-how and process advantages
Packaging and stability design	Low to moderate	Usually supports differentiation, not exclusion
Pediatric or alternative dosage forms	Variable	May create narrower, later-filed rights
Retail brand and trade dress	Moderate	Supports consumer recognition but not technical exclusivity

The most defensible commercial assets are likely to be process know-how, validated coating parameters, supplier relationships, quality systems, and retail distribution. These assets may be more valuable than a broad formulation patent.

What generic launch scenarios exist?

Scenario 1: Continued private-label price competition

This is the base commercial scenario. Multiple suppliers provide equivalent 20 mg products, and retailers compete primarily through price, count size, promotions, and shelf placement.

Scenario 2: Formulation-led differentiation

A supplier introduces a vegetarian capsule, improved moisture protection, or a smaller capsule with comparable release. The product may win a retail contract without requiring premium consumer pricing.

Scenario 3: Alternative dosage-form expansion

Granules, sprinkle products, or pediatric presentations create new segments. These products require more development but face less direct commoditization.

Scenario 4: Supply disruption

A shortage of esomeprazole magnesium, enteric polymer, capsule shells, or packaging components can shift contracts rapidly among approved suppliers. Dual sourcing and regional manufacturing capacity become commercial advantages.

Scenario 5: Retailer consolidation

Large retailers may reduce the number of approved suppliers and negotiate lower prices. Suppliers with regulatory-ready dossiers, reliable capacity, and low complaint rates are more likely to retain volume.

What licensing and partnering opportunities exist?

The most practical licensing opportunities involve technology rather than the active ingredient.

Potential transactions include:

• Licensing a delayed-release pellet platform
• Supplying proprietary enteric polymers
• Providing a ready-to-use coating dispersion
• Transferring a validated manufacturing process
• Licensing a vegetarian capsule system
• Co-developing alternative dosage forms
• Contract manufacturing under a retailer’s private label
• Regional licensing for markets with different OTC requirements

A technology owner should structure the agreement around regulatory support, change-control rights, minimum purchase volumes, supply continuity, and ownership of process improvements.

What regulatory barriers affect commercial entry?

The FDA regulatory route depends on the product’s legal basis and the applicant’s relationship to the reference product. Key requirements include:

• Active-ingredient identity and strength
• Delayed-release performance
• Stability
• Content uniformity
• Microbial quality
• Capsule integrity
• Label compliance
• Manufacturing under current good manufacturing practice
• Inactive-ingredient acceptability
• Bioequivalence or other required comparative evidence

An excipient change can trigger comparability work even when the active ingredient and nominal strength remain unchanged. The critical question is whether the change affects dissolution, stability, bioavailability, or product quality.

What is the revenue exposure for retailers and manufacturers?

Revenue exposure is generally volume-driven rather than patent-driven. A 14-count or 42-count OTC package may generate modest revenue per unit but significant aggregate volume across a national retail chain.

The main economic sensitivities are:

• Esomeprazole magnesium API price
• Enteric-polymer cost
• Coating yield
• Batch size
• Packaging format
• Retailer margin
• Promotional discounting
• Product returns
• Inventory expiration
• Manufacturing-site utilization

A one-cent reduction in delivered cost per capsule can have material annual value at national retail volumes. The highest-value technical improvements are those that lower coating consumption, reduce batch failures, extend shelf life, or increase line speed without creating regulatory rework.

Key Takeaways

• DG Health Esomeprazole Magnesium is a mature OTC private-label product based on acid-labile esomeprazole magnesium and delayed-release delivery.
• Its commercial performance depends on pellet architecture, enteric coating, moisture control, and manufacturing scale.
• Core compound exclusivity has expired, and biosimilar risk does not apply.
• The product does not have the patent profile of a newly launched branded NDA drug.
• Formulation and process patents can still affect specific suppliers, but multiple design-around options exist.
• The strongest commercial opportunities are enteric-polymer efficiency, lower coating weight, moisture protection, vegetarian capsules, and alternative dosage forms.
• Retail contracts, validated manufacturing, regulatory readiness, and supply continuity are more important barriers than compound patent protection.
• Licensing value is concentrated in coating technology, manufacturing know-how, and private-label supply arrangements.

FAQs

Is DG Health esomeprazole the same as Nexium?

It contains the same active ingredient class, esomeprazole magnesium, but the inactive ingredients, manufacturer, packaging, and regulatory application may differ.

Can a new company launch an esomeprazole 20 mg OTC product?

Yes, subject to the applicable FDA regulatory pathway, labeling requirements, product-quality standards, and manufacturing controls.

Which excipient is most important in esomeprazole capsules?

The enteric polymer is usually the most important because it controls gastric protection and intestinal release.

Does esomeprazole require a special container?

The appropriate package depends on the approved stability data. Moisture-barrier bottles, desiccants, and high-barrier blisters can be important for maintaining shelf life.

Can a formulation patent block all esomeprazole generics?

Usually not. A formulation patent may cover a specific pellet, coating, stabilizer, or release profile, but alternative excipient systems may allow a competing product to design around the claims.

References

1. U.S. Food and Drug Administration. (2023). Nexium 24HR drug facts label. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
3. U.S. Government Publishing Office. (2024). 21 U.S.C. § 355: New drugs. United States Code.